Stuttgart - Delayed Quote EUR
Gritstone bio, Inc. (2JQ.SG)
At close: October 21 at 9:31 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
496.0000
1,331.0000
9,269.0000
46,717.0000
3,462.0000
--
Operating Expense
136,961.0000
140,952.0000
129,697.0000
121,926.0000
109,479.0000
--
Operating Income
-136,465.0000
-139,621.0000
-120,428.0000
-75,209.0000
-106,017.0000
--
Net Non Operating Interest Income Expense
-1,363.0000
1,163.0000
741.0000
127.0000
703.0000
--
Other Income Expense
4,795.0000
-32.0000
--
--
--
--
Pretax Income
-133,033.0000
-138,490.0000
-119,687.0000
-75,082.0000
-105,314.0000
--
Net Income Common Stockholders
-133,033.0000
-138,490.0000
-119,687.0000
-75,082.0000
-105,314.0000
--
Diluted NI Available to Com Stockholders
-133,033.0000
-138,490.0000
-119,687.0000
-75,082.0000
-105,314.0000
--
Basic EPS
-1.09
-1.20
-1.32
-0.95
-2.79
--
Diluted EPS
-1.09
-1.20
-1.32
-0.95
-2.79
--
Basic Average Shares
123,611.3870
115,527.5460
90,918.3330
78,885.1860
37,792.3650
--
Diluted Average Shares
123,611.3870
115,527.5460
90,918.3330
78,885.1860
37,792.3650
--
Total Operating Income as Reported
-136,465.0000
-139,621.0000
-120,428.0000
-75,209.0000
-106,017.0000
--
Total Expenses
136,961.0000
140,952.0000
129,697.0000
121,926.0000
109,479.0000
--
Net Income from Continuing & Discontinued Operation
-133,033.0000
-138,490.0000
-119,687.0000
-75,082.0000
-105,314.0000
--
Normalized Income
-133,033.0000
-138,490.0000
-119,687.0000
-75,082.0000
-105,314.0000
--
Interest Income
3,445.0000
5,199.0000
1,976.0000
164.0000
715.0000
--
Interest Expense
4,808.0000
4,036.0000
1,235.0000
37.0000
12.0000
--
Net Interest Income
-1,363.0000
1,163.0000
741.0000
127.0000
703.0000
--
EBIT
-128,225.0000
-134,454.0000
-118,452.0000
-75,045.0000
-105,302.0000
--
EBITDA
-120,994.0000
-126,863.0000
-111,892.0000
-68,698.0000
-98,658.0000
--
Reconciled Depreciation
7,231.0000
7,591.0000
6,560.0000
6,347.0000
6,644.0000
--
Net Income from Continuing Operation Net Minority Interest
-133,033.0000
-138,490.0000
-119,687.0000
-75,082.0000
-105,314.0000
--
Normalized EBITDA
-120,994.0000
-126,863.0000
-111,892.0000
-68,698.0000
-98,658.0000
--
12/31/2019 - 12/28/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MWG0.SG InMed Pharmaceuticals Inc
0.2980
+12.88%
BT1.SG Bone Therapeutics SA
0.0103
+30.38%
MWG0.BE InMed Pharmaceuticals Inc
0.2795
+5.47%
MWG0.F InMed Pharmaceuticals Inc.
0.2485
-2.74%
BT1.F BioSenic S.A.
0.0055
-30.38%
BT1.BE Bone Therapeutics SA
0.0093
+5.68%
LMQ.BE Oxford BioDynamics PLC
0.0155
0.00%
1IY0.MU MONOPAR THERAP. NEW
4.8400
0.00%
2DE0.MU Genprex Inc
0.5400
0.00%
AREC.L Arecor Therapeutics plc
77.00
+3.36%